NIP
APLS

Nicholas Investment Partners’s Apellis Pharmaceuticals APLS Stock Holding History

Nicholas Investment Partners’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-414,419
Closed -$37.8M – 186
2023
Q2 		$37.8M Buy
414,419
+77,468
+23% +$6.68M 2.58% 3
2023
Q1 		$22.2M Buy
336,951
+88,668
+36% +$5.12M 1.69% 18
2022
Q4 		$12.8M Buy
248,283
+53,770
+28% +$2.85M 1.12% 35
2022
Q3 		$13.3M Buy
194,513
+69,018
+55% +$4.08M 1.23% 26
2022
Q2 		$5.67M Buy
125,495
+63,495
+102% +$2.9M 0.54% 69
2022
Q1 		$3.15M Buy
+62,000
New +$2.74M 0.22% 123

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Nicholas Investment Partners's APLS Position: Q3 2023 in Review

Nicholas Investment Partners sold out of Apellis Pharmaceuticals (APLS) in Q3 2023, closing a stake of 414,419 shares — an estimated $37.8M sold.

Nicholas Investment Partners first reported a position in APLS in Q1 2022 and held it in 6 quarters. The position peaked at $37.8M in Q2 2023. 256 funds tracked by Wall St. Rank hold APLS as of Q3 2023.

  • Nicholas Investment Partners reported no remaining Apellis Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Nicholas Investment Partners sold 414,419 Apellis Pharmaceuticals shares in Q3 2023, an estimated $37.8M.
  • Nicholas Investment Partners first reported a position in Apellis Pharmaceuticals in Q1 2022 and held it in 6 quarters.
  • Nicholas Investment Partners's Apellis Pharmaceuticals position peaked at $37.8M in Q2 2023.
  • 256 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2023.

Based on Nicholas Investment Partners's 13F filing for Q3 2023, filed 13 Nov 2023.